Table 3.
Effects of the two treatments on oxidative stress parameters
| Losartan+barnidipine | Losartan+lercanidipine | ||||
|---|---|---|---|---|---|
| Baseline | End of study | Baseline | End of study | p for interaction between groups | |
| N | 75 | 72 | 76 | 71 | - |
| Sex (male/female) | 37/38 | 36/36 | 36/40 | 35/36 | ns |
| BMI (Kg/m2) | 28.5 ± 1.3 | 28.4 ± 1.2 | 28.2 ± 1.1 | 28.1 ± 1.0 | ns |
| Fasting plasma glucose (mg/dl) | 129.6 ± 9.7 | 125.8 ± 9.1 | 130.1 ± 10.2 | 127.6 ± 9.9 | ns |
| HbA1c (%) | 7.0 ± 0.5 | 6.9 ± 0.4 | 6.9 ± 0.4 | 7.0 ± 0.5 | ns |
| Hs-CRP (mg/l) | 1.7 ± 0.9 | 1.2 ± 0.4* | 1.6 ±0.8 | 1.5±0.6 | 0.047 |
| TNF-α (ng/ml) | 2.9 ± 1.7 | 2.2 ± 1.3* | 2.8 ± 1.6 | 2.6 ± 1.4 | 0.042 |
| MMP-2 (ng/ml) | 1216.5 ± 124.1 | 965.1 ± 102.6* | 1218.8 ± 126.8 | 978.3 ± 106.2* | ns |
| MMP-9 (ng/ml) | 465.1 ± 50.1 | 382.5 ± 46.3* | 462.2 ± 49.4 | 394.1 ± 48.5* | ns |
| sVCAM-1 (ng/ml) | 637.8 ± 172.5 | 536.1 ± 112.7* | 638.4 ± 173.1 | 592.7 ± 141.6 | 0.041 |
| sICAM-1 (ng/ml) | 201.5 ± 12.8 | 174.2 ± 8.1* | 204.2 ± 13.3 | 198.6 ± 11.2 | 0.046 |
| Isoprostanes (pg/ml) | 114.3 ± 39.2 | 92.5 ± 28.5* | 110.2 ± 36.8 | 103.4 ± 33.2 | 0.047 |
| PON-1 (U/l) | 160.5 ± 85.2 | 182.5 ± 99.2 | 157.1 ± 83.4 | 177.2 ± 95.7 | ns |
Data are means ± SD
*p < 0.05 vs baseline
BMI body mass index, FPI fasting plasma insulin, HbA 1c glycated hemoglobin, Hs-CRP high-sensitivity C-reactive protein, TNF-α tumor necrosis factor-α, MMP-2 metalloproteinase-2, MMP-9 metalloproteinase-9, sVCAM-1 soluble vascular adhesion protein-1, sICAM-1 soluble intercellular adhesion protein-1, PON-1 paraoxonase-1